Current and future perspectives of PD‐1/PDL‐1 blockade in cancer immunotherapy
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has
yielded great success in recent years. Among immunotherapeutic agents, immune …
yielded great success in recent years. Among immunotherapeutic agents, immune …
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
J Qu, Q Mei, L Chen, J Zhou - Cancer immunology, immunotherapy, 2021 - Springer
There has been a rapid progress in developing genetically engineered T cells in recent
years both in basic and clinical cancer studies. Chimeric antigen receptor (CAR)-T cells …
years both in basic and clinical cancer studies. Chimeric antigen receptor (CAR)-T cells …
[HTML][HTML] The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and …
C Liu, S Zheng, R Jin, X Wang, F Wang, R Zang, H Xu… - Cancer letters, 2020 - Elsevier
Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …
Antigen presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier immunity
AT Shenoy, C Lyon De Ana, EI Arafa, I Salwig… - Nature …, 2021 - nature.com
Barrier tissues are populated by functionally plastic CD4+ resident memory T (TRM) cells.
Whether the barrier epithelium regulates CD4+ TRM cell locations, plasticity and activities …
Whether the barrier epithelium regulates CD4+ TRM cell locations, plasticity and activities …
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
C Liu, S Zheng, Z Wang, S Wang, X Wang… - Cancer …, 2022 - Wiley Online Library
Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …
Use of real‐world evidence to drive drug development strategy and inform clinical trial design
S Dagenais, L Russo, A Madsen… - Clinical …, 2022 - Wiley Online Library
Interest in real‐world data (RWD) and real‐world evidence (RWE) to expedite and enrich the
development of new biopharmaceutical products has proliferated in recent years, spurred by …
development of new biopharmaceutical products has proliferated in recent years, spurred by …
Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
C Liu, L Yang, H Xu, S Zheng, Z Wang, S Wang… - BMC medicine, 2022 - Springer
Background Cytokines have been reported to alter the response to immune checkpoint
inhibitors (ICIs) in patients with the tumor in accordance with their plasma concentrations …
inhibitors (ICIs) in patients with the tumor in accordance with their plasma concentrations …
FDA Approval summary: Pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of Advanced/Metastatic PD-L1–high NSCLC
O Akinboro, E Larkins, LH Pai-Scherf, LN Mathieu… - Clinical Cancer …, 2022 - AACR
FDA's approval of cemiplimab-rwlc on February 22, 2021, follows prior approvals of
pembrolizumab and atezolizumab for similar indications as first-line treatment for patients …
pembrolizumab and atezolizumab for similar indications as first-line treatment for patients …
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Purpose We aimed to evaluate if imaging biomarkers on FDG PET are associated with
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients
XZ Huang, P Gao, YX Song, Y Xu, JX Sun… - …, 2019 - Taylor & Francis
The gut microbiota plays a critical role in the anti-tumor immune response. There is
increasing data showing that antibiotics (ATBs) change the composition of the gut microbiota …
increasing data showing that antibiotics (ATBs) change the composition of the gut microbiota …